ROG.SW Stock Risk & Deep Value Analysis

ROG.SW

Healthcare • Drug Manufacturers - General

DVR Score

0.5

out of 10

Distressed

What You Need to Know About ROG.SW Stock

We analyzed ROG.SW using our deep value framework. Sign in to see our full verdict and DVR Score.

We ran ROG.SW through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Moderate. Here's what we found.

Updated Mar 16, 2026•Run Fresh Analysis →

How Risky Is ROG.SW Stock?

Overall Risk

Moderate

Financial Risk

Low

Market Risk

Low

Competitive Risk

Medium

Execution Risk

Low

Regulatory Risk

Medium

What Are the Red Flags for ROG.SW?

⚠
Failure of a pivotal late-stage clinical trial
⚠
Increased competitive pressure from biosimilars on blockbuster drugs
⚠
Unfavorable regulatory changes impacting drug pricing or market access
⚠
Major patent expirations leading to revenue erosion

Unlock ROG.SW Red Flags & Risk Warnings

Create a free account to see the full analysis

What Does ROG.SW (ROG.SW) Do?

Market Cap

$243.97B

Sector

Healthcare

Industry

Drug Manufacturers - General

Employees

103,249

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. The company was founded in 1896 and is based in Basel, Switzerland.

Visit ROG.SW Website

Is ROG.SW Stock Undervalued?

Roche Holding AG (ROG.SW) remains a fundamentally robust mega-cap pharmaceutical and diagnostics leader. Its formidable R&D pipeline, established market dominance, strong financials, and diversified portfolio ensure stability, incremental growth, and consistent shareholder returns. However, its immense scale (estimated market cap around CHF 225 billion as of early March 2026) inherently constrains its capacity for 10x growth within a 3-5 year horizon. The company's growth stems from new drug approvals and market share defense in mature, highly regulated sectors, which typically do not yield the exponential market creation or disruption requisite for such an aggressive return profile. No material changes have occurred since the last analysis (2026-03-06) to alter this fundamental assessment. Thus, while an excellent choice for stability and income, it does not align with the high-risk, high-reward, 10x growth criteria.

Unlock the full AI analysis for ROG.SW

Get the complete DVR score, risk analysis, and more

Is ROG.SW Financially Healthy?

P/E Ratio

25.88

Does ROG.SW Have a Competitive Moat?

Moat Rating

🏰 Wide

Moat Trend

Stable

Moat Sources

4 Identified

Intangible Assets/IPBrand PowerCost AdvantagesSwitching Costs

Roche's moat is highly durable, driven by continuous innovation, a vast patent portfolio, strong regulatory expertise, and the integrated pharma/diagnostics model creating high switching costs for healthcare providers and patients.

Moat Erosion Risks

•Significant patent expirations without adequate pipeline replacement
•Disruptive competitive therapies that render existing treatments obsolete
•Adverse shifts in global healthcare policies or reimbursement structures

ROG.SW Competitive Moat Analysis

What Could Drive ROG.SW Stock Higher?

Near-Term (0-6 months)

•Q1 2026 Earnings Report (estimated mid-April 2026)
•Key Phase 3 clinical trial readouts for pipeline assets (e.g., neuroscience, oncology)
•Regulatory submission or approval for new drug indications in major markets

Medium-Term (6-18 months)

•Launch of novel diagnostics platforms or assays
•Expansion of personalized healthcare initiatives into new regions
•Strategic partnerships to bolster specific therapeutic areas or technology platforms

Long-Term (18+ months)

•Sustained leadership in oncology and diagnostics through continuous innovation
•Integration of AI/machine learning across R&D and precision medicine
•Addressing unmet medical needs in rare diseases and neurodegenerative conditions

Catalysts & Growth Drivers

Upgrade to Premium to see catalysts

What's the Bull Case for ROG.SW?

✓
Success rate of pivotal clinical trials for new drugs (Phase 3)
✓
Trends in diagnostics market growth and Roche's market share within it
✓
Impact of biosimilars on key blockbuster drug revenues and gross margins
✓
Any changes in the company's dividend policy or growth rate

Bull Case Analysis

See what could go right with Premium

📊 Explore More Stock Analysis

Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.

Analyze Any Stock →View Top 100 Deep Value Stocks →

Important Disclaimer – Not Financial Advice

Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for ROG.SW (ROG.SW) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.

All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.